Rapport Therapeutics (NASDAQ:RAPP) Price Target Raised to $82.00

Rapport Therapeutics (NASDAQ:RAPP) had its price objective hoisted by JonesTrading from $50.00 to $82.00 in a report released on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities analysts also recently issued reports about the company. Leerink Partners assumed coverage on Rapport Therapeutics in a report on Wednesday, June 24th. They issued an “outperform” rating and a $52.00 price objective on the stock. William Blair started coverage on Rapport Therapeutics in a report on Tuesday, July 28th. They set an “outperform” rating for the company. HC Wainwright reissued a “buy” rating and set a $66.00 target price on shares of Rapport Therapeutics in a research report on Tuesday. Wells Fargo & Company dropped their target price on shares of Rapport Therapeutics from $51.00 to $50.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $86.00 price target on shares of Rapport Therapeutics in a report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Rapport Therapeutics has an average rating of “Buy” and an average price target of $68.36.

Rapport Therapeutics Stock Down 2.3%

Shares of RAPP opened at $25.93 on Wednesday. Rapport Therapeutics has a twelve month low of $23.75 and a twelve month high of $52.93. The stock’s fifty day simple moving average is $39.01 and its 200 day simple moving average is $38.93.

Rapport Therapeutics (NASDAQ:RAPP) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). On average, sell-side analysts predict that Rapport Therapeutics will post -4.08 earnings per share for the current year.

Insider Buying and Selling at Rapport Therapeutics

In other Rapport Therapeutics news, Director John Maraganore purchased 9,411 shares of the firm’s stock in a transaction that occurred on Thursday, October 22nd. The stock was purchased at an average cost of $26.45 per share, with a total value of $248,920.95. Following the transaction, the director owned 9,411 shares in the company, valued at approximately $248,920.95. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Abraham Ceesay sold 28,958 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the sale, the chief executive officer directly owned 486,108 shares of the company’s stock, valued at approximately $23,338,045.08. This trade represents a 5.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have acquired 61,694 shares of company stock worth $1,664,818 and have sold 100,186 shares worth $4,484,793. Insiders own 12.48% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of RAPP. KBC Group NV acquired a new stake in shares of Rapport Therapeutics in the first quarter valued at about $30,000. Sterling Capital Management LLC raised its holdings in shares of Rapport Therapeutics by 597.9% during the 3rd quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock valued at $33,000 after buying an additional 843 shares during the period. State of Wyoming purchased a new stake in shares of Rapport Therapeutics during the 2nd quarter valued at about $65,000. Meeder Asset Management Inc. purchased a new stake in shares of Rapport Therapeutics during the 2nd quarter valued at about $116,000. Finally, AlphaCentric Advisors LLC lifted its position in Rapport Therapeutics by 6.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock worth $201,000 after acquiring an additional 408 shares in the last quarter.

Key Headlines Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 met both Phase 2 endpoints in bipolar mania. The drug delivered statistically significant placebo-adjusted improvements in mania scores, and Rapport plans to advance it into Phase 3. Success could expand RAP-219’s opportunity beyond epilepsy and materially increase the company’s pipeline value. Rapport Therapeutics Phase 2 results
• Positive Sentiment: Analysts remain optimistic and raised price targets. JonesTrading lifted its target to $82, BTIG to $89 and Raymond James to $86, while HC Wainwright maintained a Buy rating. The reported consensus target of approximately $68.36 implies substantial upside from recent levels. Rapport Therapeutics analyst price target
• Positive Sentiment: Multiple insiders bought shares on the open market. CFO Troy Ignelzi purchased 5,500 shares, while directors Steven Paul, John Maraganore, Wendy Young, Paul Silva and Ramiro Sanchez also bought shares. The purchases totaled roughly $1.8 million based on the disclosed transactions and may signal management confidence following the clinical update. Rapport Therapeutics insider buying
• Neutral Sentiment: An analysis suggested Rapport could be significantly below estimated fair value following the Phase 2 results, but that valuation depends on successful Phase 3 development, regulatory approval and eventual commercialization.
• Negative Sentiment: Investors may have viewed the clinical win as less decisive than hoped. Reports indicated that some portions of the data only narrowly met expectations, potentially prompting profit-taking after the initial rally. Rapport bipolar mania data analysis
• Negative Sentiment: Rapport remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss missed analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. CEO Abraham Ceesay also sold 2,210 shares, a relatively small reduction of 0.49% in his holdings, which contrasts with the broader insider buying. SEC CEO ownership filing

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.